{"id":"NCT00264875","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy","officialTitle":"An Open-Label, Extension Safety And Efficacy Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With Human Immunodeficiency Virus (HIV) Neuropathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2008-02","completion":"2008-02","firstPosted":"2005-12-13","resultsPosted":"2009-03-23","lastUpdate":"2021-01-22"},"enrollment":220,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Peripheral Neuropathy","HIV Infections"],"interventions":[{"type":"DRUG","name":"pregabalin","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and efficacy of pregabalin in reducing neuropathic pain associated with HIV neuropathy","primaryOutcome":{"measure":"Mean Visual Analogue Scale (VAS) Pain Scores","timeFrame":"Baseline, Week 4, Week 8, Week 12, and Endpoint","effectByArm":[{"arm":"Pregabalin","deltaMin":38.61,"sd":27.1}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":37,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081095&StudyName=Open%20Label%20Safety%20And%20Efficacy%20Study%20Of%20Pregabalin%20In%20Subjects%20With%20Nerve%20Pain%20Asociated%20With%20HIV%20Neuropathy"]},"adverseEventsSummary":{"seriousAny":{"events":10},"commonTop":["Dizziness","Somnolence","Peripheral edema","Diarrhea","Fatigue"]}}